1[1]Marra F, Gentilini A, Pinzani M, et al. Phosphatidylinositol 3-Kinase is required for platelet-derived growth factor's actions on hepatic stellate cells. Gastroenterology, 1997,112:1297-1306.
2[2]Rockey DC. The cellular pathogenesis of portal hypertension: Stellate cell contractility, endothelin and nitric oxide, Hepatology, 1997,25: 2-5.
3[3]Friedman SL. Cytokines and fibrogenais. Semin liver Dis, 1999, 19:129-140.
4[4]Tsukamoto H. Is inferleukin-10 antifibrogenic in chronic liver injury?Hepatology, 1998,28:1707-1709.
5[5]Iredale JP, Murphy G, Hembry RM, et al. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1 (TIMP-1):implications for regulation of matrix degradation in liver. J Clin Invest, 1992,90: 282-287.
7Farzaneh - Far R, Moore K. Nitric oxide and the liver. Liver, 2001 ; 21(3):161.
8Moreau R, Barriem E, Taft KA, et al. Teflipressin inhibits in vivtrugdc iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis. Hepatology, 2002; 36(5) : 1070.
9Mcnaughton L, Puttagunta L, Martinez - Cuesta MA, et al. Distribution of nitric oxide synthase in nomud and cirrhotic human liver. Proc Nail Acad Sci USA,2002;99(26) :17161.
10Dogru - Abbasoglu S, Balkan J, Kanbagli O, et al. Aminoguanidine, aninducible nitric oxide syntbase inhibitor, plus N - acetylcysteine trealanent reduce the lipopolysaccharide - augmented hepatotoxicity in rats with cirrhosis. Hum Exp Toxicol, 2002 ;21 (7) :359.
